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Abstract 
One of the features of advanced life sciences research in recent years has been its internationalisation, with 
countries such as China and South Korea considered ‘emerging biotech’ locations. As a result, cross-
continental collaborations are becoming common generating moves towards ethical and legal 
standardisation under the rubric of ‘global bioethics’. Such a ‘global’, ‘Western’ or ‘universal’ bioethics 
has in turn been critiqued as an imposition upon resource-poor, non-Western or local medical settings. In 
this article, we propose that a different tack is necessary if we are to come to grips with the ethical 
challenges that inter-continental biomedical research collaborations generate. In particular we ask how 
national systems of ethical governance of life science research might cope with increasingly global 
research collaborations with a focus on Sino-European collaboration. We propose four ‘spheres’ – 
deliberation, regulation, oversight and interaction – as a helpful way to conceptualise national systems of 
ethical governance. Using a workshop-based mapping methodology we identified three specific ethical 
challenges arising from cross-continental research collaborations: 1) ambiguity as to which regulations are 
applicable; 2) lack of ethical review capacity not only among ethical review board members but also 
collaborating scientists; 3) already complex, researcher-research subject interaction is further complicated 
when many nationalities are involved. 
 
 
 
Introduction 
In November 2008, a few hundred pharmaceutical industry representatives from China, 
Europe and other parts of the world met in Shanghai for China Trials 2008 an event 
billed by its organisers as “Your gateway to conducting clinical trials in China... If you’re 
an emerging biotech or pharma company interested in conducting trials in China, you will 
learn exactly how much time and money you can save, how acceptable your China data is 
for submission to the FDA/EMEA” (China Trials 2008). A few months later, in February 
2009, the Sino-Danish Breast Cancer Research Centre was inaugurated bringing together 
Danish and Chinese geneticists with an aim “to solve some of the most urgent problems 
in modern treatment of breast cancer” (BCRC 2012). 
 
What kinds of ethical challenges does such an ongoing globalisation of biomedical 
research collaborations give rise to ‘on the ground’ in all those spaces and processes 
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where bench and bedside intersect and overlap? From a biomedical point of view 
research depends, on the one hand, on volunteer human subjects – either as donors of 
human biological materials (e.g. gametes, embryos, blood, bone marrow, tissue) and/or 
biographical information (e.g. medical history, lifestyle details, socio-economic 
background), or as participants in clinical research (e.g. in randomised controlled trials or 
as recipients of experimental therapies) – and on the other, scientists, medical 
professionals as well as other research support staff who operate within particular 
regulatory, socio-economic, technological, institutional and cultural settings. At the same 
time, standardized technological developments have made it possible to globalise 
research as biological samples procured in one place, can be biologically cultured and/or 
biochemically/genetically analysed in another, and the information derived can be 
digitalised and electronically transported throughout the world together with associated 
biographical information. This also means that biomedical treatments developed in one 
place can be transferred to another country or region for clinical testing. 
 
In this article, we ask how national systems of ethical governance of these kinds of 
biological and biomedical research might cope with increasingly global life science 
research collaborations with a specific focus on Sino-European biomedical research 
collaboration. Ethical governance is not just about how guidelines and regulations are 
implemented and followed. Rather, it involves a complex system whereby research 
practice is guided not only by requirements of scientific rigour but equally importantly by 
respect for the rule of law, transparency, scientific and ethical accountability and freedom 
from corruption. Our guiding research question has been: what happens when biomedical 
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research collaboration is initiated across continents involving multiple legal systems, 
administrative requirements, ethical review procedures, socio-economic conditions and 
cultural contexts? It is the ethical challenges that emerge specifically as a result of the 
exchange of researchers, biomedical treatments, scientific equipment, biological 
materials, sequencing data and/or information databases across continents and countries 
that will be analysed and discussed in the following. 
 
One response to the ongoing globalisation of biomedical research has been a concerted 
effort to achieve some kind of global consensus around core bioethical principles led by, 
for example, UNESCO, WHO and the Council for International Organizations of 
Medical Sciences (CIOMS). Through a series of guidelines and declarations, these 
organisations have called for a ‘global bioethics’: “a universal framework of principles 
and procedures to guide States in the formulation of their legislation, policies or other 
instruments in the field of bioethics” (UNESCO 2005). At the same time, nation states 
are of course engaged in building up their own national infrastructures of ethical 
governance of biomedical research. We therefore argue that a change of tack is necessary 
– from focussing on global bioethics to the ethical governance of global biomedical 
research collaborations – if we are to understand the challenges that arise ‘on the ground’ 
when nationally-anchored procedures of ethical governance intersect in contexts of global 
collaboration. 
 
We begin this article by highlighting three important sets of critiques of global bioethics 
as a way to contextualise our own approach to examining national infrastructures of 
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ethical governance. We then set out our workshop-based methodology, which was 
designed as a mapping exercise to document already existing or emerging ethical 
governance practices, structures and challenges in China and Europe, within the specific 
fields of regenerative medicine, genomic and clinical research over three years 
(November 2006 to September 2009). In the main section of the article, we present our 
explorative findings through our discussion of the ways in which distinct national 
systems of ethical governance are challenged by global biomedical research 
collaborations. We have found it empirically helpful to distinguish between four 
important ‘layers’ or ‘spheres’ that make up systems of ethical governance of biological 
and biomedical research. Firstly, many countries (not least in Europe and China) have 
developed organised processes of national ethical deliberation in order to debate science 
directions as a matter of stewardship. Secondly, these same countries have also, 
especially since the latter half of the 20th century, formulated and passed various types of 
ethical regulation whether in the form of laws, guidelines or standards. Thirdly, these 
various forms of ethical regulation often stipulate mandatory ethical oversight of 
biomedical research involving volunteer human subjects with the ethics review 
committee or institutional review board as the dominant organisational form. And finally, 
ethical interaction consists of all those moments when scientists/clinicians and research 
subjects/patients come into contact with each other, whether in contexts of recruitment, 
participation or follow-up in a biomedical research project. 
 
Each layer or sphere, and the various ways in which they overlap and interact, forms a 
part of national ethical governance infrastructures. And while each sphere merits specific 
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attention in and of themselves in any country, in this paper we identify the specific 
challenges that arise in each of these spheres when national systems of ethical 
governance intersect in the context of cross-continental research collaboration. 
 
Global biomedicine, global bioethics 
Over the last two decades, a number of scholars have critically examined the unfolding 
globalisation of biomedical research, while also pointing to colonial legacies of medical 
‘field’ research (see Angell 1997; Varmus & Satcher 1997; Mbidde 1998; Sunder Rajan 
2006; Bharadwaj 2009; Gottweis 2009; Sleeboom-Faulkner 2009 & 2010; Petryna 2009; 
Ong 2010; Crane 2010; Geissler & Molyneux 2011). What they have shown is that 
alongside the globalisation of biomedical research in recent years, we have also seen 
“growing moves towards ethical, legal and regulatory standardisation around the globe” 
(Bharadwaj 2009: 96) as “the dispersal of genetic science across the world raises 
questions about the interactions of biotechnologies and bioethics in diverse global 
locations” (Ong 2010: 1). Critical studies of formalistic bioethics – as found in 
declarations, principles, guidelines and regulations – have long highlighted problems that 
can arise when a universalised set of principles travels out into a ‘messy’ field only to be 
‘operationalised’ in diverse historical, cultural and socio-economic contexts (see Crane 
2010). We might broadly distinguish between three forms of critique which are related to 
1) resource-poor settings, 2) culture and value dimensions and 3) so-called ‘situational 
ethics’. 
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The first of these sets of critique focuses on the problem of harmonizing ethical review 
practices “in the ‘overseas’ situation of unequal scientific and technical capacity and 
great disparities in power and wealth” (Geissler & Molyneux 2011: 2; see also Bhutta 
2004; Crane 2010; Resnik 1998, DeCosta et al. 2004, Molyneux et al. 2005, Geisler et al. 
2008). Such critiques point to the material, technical, regulatory and capacity-related 
challenges of ensuring ethical oversight and protection when research is carried out in so-
called ‘resource-poor’ settings which are seen as particularly vulnerable. 
 
A second set of critiques has focused on the ‘Eurocentric’ basis of bioethical principles as 
espoused in such documents as the Helsinki Declaration or the Universal Declaration on 
Bioethics and Human Rights: “Western moral analyses, processes, and solutions are not 
transportable to all bioethical contexts around the world… [rather they] must be recast 
radically to take account of the particular moral context that defines the complex 
character of [east Asian] culture” (Alora & Lumitao 2001: 4; see also Qiu 2004; Tangwa 
1996). This line of cultural critique, which has especially (but not only) developed in 
Asia, speaks against a perceived ‘ethical imperialism’ and calls for cross-cultural 
dialogues based on mutual understanding and respect. 
 
Finally, a third set of critiques has emerged out of ethnographic engagement with those 
communities within which biomedical research is taking place. In these critiques, 
“anthropologists have variously posed relational and situational ethics as counters to the 
claims of universal systemic ethics” (Ong 2011: 12; see also Petryna 2007; Bharadwaj 
2009; Sleeboom-Faulkner 2010; Molyneux & Geissler 2008), since ethics are seen as 
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emerging in response to particular practices rather than as something that can be imposed 
from without. Ethnographic studies of ‘research subject communities’ show how there is 
considerable ‘ethical variability’ or ‘ethical flexibility’ depending on the context within 
which research is being carried out, most visibly perhaps in contexts of public health 
crisis, raising questions about the feasibility of a universalised bioethics. 
 
Each of these three forms of critique is premised on the imposition of an ethical 
framework (‘Western’ or ‘universal’) considered external, detached or alien to a given 
situation. In this article we shift focus to the specific ethical challenges that inter-
continental biomedical research collaborations generate. That is to ask, what happens 
when scientists from two different continents join forces to engage in cross-border 
collaborative research? For if it is the case that individual countries are actively building 
up national structures and procedures for the ethical governance of biological and 
biomedical research then it is necessary to consider how such national systems of ethical 
governance might cope with increasingly global life science research collaborations. 
 
Methodology – mapping ethical governance practices 
The data for this article has been generated through a large-scale Sino-European 
collaboration over a three-year period (2006-2009) called BIONET. A total of five 
explorative workshops and conferences were held in cities throughout China (Beijing, 
Shanghai, Changsha, Xian and Shenzhen) focusing on the fields of 1) reproductive and 
regenerative medicine; 2) clinical trials; and 3) biobanking and genomic research. A final 
conference was organised in London to identify and reflect on key findings and to 
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identify avenues for future collaboration. The objective of these events was to map out 
ethical governance practices in China and Europe within these fields of biomedical 
research as a way to inform, prepare, inspire and facilitate cross-cultural exchange on 
matters of common concern as well as to begin thinking about what ethical governance of 
international research collaborations might look like.  
 
The workshops and conferences were each approximately five days in length and 
included fifty to sixty participants with a core group of people who attended all of them 
which provided overlap. Systematic mapping research was carried out by BIONET 
partners and by a group of post graduate students who had competitively applied for 
BIONET research grants. 
 
All in all the events were attended by approximately 300 clinicians, life scientists, 
lawyers, ethicists, government officials, policymakers, social scientists and others from 
China and Europe with specific expertise and experience in the fields of research that 
were being explored. Participants were not representative of either China or Europe, but 
were actively engaged with issues around the ethical governance of biomedical research 
in both regions. Workshops and conferences consisted of presentations on the current 
state of ethical governance of advanced biomedical research in both China and Europe 
with ample time for discussion and debate between European and Chinese participants. 
Speakers were asked to identify key ethical challenges arising from stem cell, clinical and 
genomics research from their respective disciplinary perspectives. Presentations and 
discussions were recorded and reports were prepared from each event summarising key 
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discussions and presentations. Simultaneous translation was provided at all events to 
facilitate dialogue (for a complete description of our methodology see BIONET 2010a). 
The project was carried out in accordance with the ethical requirements of the European 
Commission. 
 
Our findings, as presented in the following, are not mere summaries of the discussions at 
our workshops. Rather, they are the result of a synthesis and organisation of the main 
challenges and themes identified throughout the BIONET project. A BIONET Expert 
Group consisting of life scientists, ethicists, philosophers and social scientists contributed 
to the identification of key topics and issues for discussion (BIONET 2010b) and the 
BIONET group of core scholars met regularly to synthesise and organise the main 
lessons and findings from each BIONET event. 
 
We have been acutely aware of the limitations of time and outreach, and as a result we 
make no claims about the ethnographic, representative or definitive value of our findings. 
Instead we suggest that the presentations, debates and discussions that we have 
systematically recorded and synthesised in the following allow us to identify important 
challenges for future attention as cross-cultural biomedical research collaborations 
increase in scope and number. 
 
Findings and discussion: ethical governance of cross-cultural research collaboration 
Stem cell research, clinical trials and biobanking are very different kinds of biomedical 
research, each with its particular forms of expertise, infrastructural requirements and 
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material bases. Yet what they have in common is the challenge of coordination when 
large-scale research projects are set in motion. From the perspective of researchers, grant 
applications have to be prepared, laboratories and clinics have to be built and maintained, 
databases have to be generated and managed, biological samples have to be collected, 
and volunteers have to be recruited. Moreover, the reliance of advanced biomedical 
research on human volunteers means that not only is administrative compliance required, 
so too is ethical adherence as research protocols must be ethically reviewed and approved 
by ethical review boards and volunteer recruitment processes ethically overseen. This can 
be challenging enough to coordinate within the confines of a single administrative or 
bureaucratic system. What then if biomedical research collaboration is initiated across 
continents involving multiple legal systems, administrative requirements, ethical review 
procedures, socio-economic conditions and cultural contexts? 
 
As noted earlier, this was a guiding question for us during the course of the discussions 
and debates that took place at the workshops and conferences held in the period 2006 to 
2009. We deliberately chose to focus on ethical governance in the fields of regenerative 
medicine, clinical trials and biobanking rather than on bioethics as such, as this allowed 
us to shift analytical attention to the practices that make up such systems of ethical 
governance, and thereby to explore embedded ethical approaches and unexpected 
conceptualizations or models of practice. What we found in both China and Europe was 
that over the last decades, countries have been actively building up infrastructures of 
ethical governance as a means to organize and ensure the protection of those human 
subjects who take part in medical research as donors, participants or scientists involved in 
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challenging innovative research. And, in both regions questions of harmonisation and 
standardisation have been among the most challenging. Different, however, were the 
particular configurations within these systems; differences, which could be traced out 
within what we came to think of as ‘spheres’ or ‘layers’ of ethical governance. Each layer 
or sphere, and the various ways in which they overlap and interact, forms a part of ethical 
governance systems or regimes. As such, if we are to understand the specific ethical 
challenges that arise out of trans-national and cross-cultural biomedical research 
collaborations, then we must have a clear understanding of what each participating 
scientist/institution ‘brings’ to a collaboration. 
 
In the following we will introduce each of these spheres – of ethical deliberation, ethical 
regulation, ethical oversight and ethical interaction – as a way to present some of the 
differences and challenges we identified during the course of our project. Importantly, 
these were not only differences between China and Europe, but also often between 
European countries and between provinces/regions within China. 
 
Organising national deliberation – participatory vs. expert-based governance 
The specific terms under which national ethical governance systems are being built up 
are often ‘set’ through some form of ethical deliberation – a kind of national deliberative 
space in which science directions are debated. Advanced life sciences research has raised 
a number of specific questions, among scientists and within societies, related to whether 
or not (and if so in what manner) certain types of biological manipulation of human life 
should be restricted or prohibited in controlled laboratory settings (e.g. creation of 
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embryos for research, creation of human-animal cybrids or human cloning). Debates 
about whether it should be permissible and / or fundable to manipulate and experiment on 
human zygotes or whether or not enucleated rabbit eggs should be filled with human 
adult cells have become public affairs, in terms of morality, scientific acceptability and 
eligibility for funding with public money. 
 
But how do deliberations about direction in scientific research take place in different 
countries? Is it possible to speak of different forms of stewardship, specific to each 
national setting (cf. Jasanoff 2007)? In both China and Europe, national ethics 
commissions and councils have been created to monitor developments in the life sciences 
as well as to feed into policy processes. Yet, the ways in which a national ‘position’ has 
emerged in each country around what forms and manner of life science research should 
be allowed, restricted or prohibited has been very different. Moreover, national positions 
can express different views or interests on different levels, such as those of the public, the 
government, powerful stakeholders, etc., which might not be directly comparable 
between countries. 
 
If, in Europe, one might speak of a new form of ‘participatory governance’ in the life 
sciences arena as “areas of administration and governance that were previously the 
exclusive domain of technical experts and of meetings behind closed doors are being 
opened up to public scrutiny and participation” (PAGANINI 2007: 9), then in China we 
might speak of ‘expert governance’ where the Ministry of Health and the Ministry of 
Science and Technology assemble committees with mandates to “carry out researches 
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and discussions on major ethical issues and put forward their consultative opinions on 
policies” (MOH 2007: Article 5). 
 
The main differences in forms of stewardship between PRC and Europe (and indeed 
within these two areas) we identified pertained to the extent to which “inclusion, 
involvement and mobilisation of extrascientific actors and perspectives are built into a 
discursive and institutional framework” (Braun & Kropp 2010: 780).  In Europe, it is 
perhaps especially civil society actors such as religious groups, patient groups and 
professional organisations that have been particularly vocal in national ethical 
deliberation, although each European country has its particularities. While in China, a 
growing bioethics community has begun engaging not only with scientists and clinicians 
through capacity-building workshops but also with the public by calling for more 
deliberation about biological research (Sleeboom-Faulkner & Hwang 2012). The 
Ministry of Health’s Ethics Committee is planning to publish its findings and opinions to 
encourage discussion among scientists, clinicians as well as the public. The media in 
China have also begun playing a role in stimulating deliberation around bioethical issues, 
though as some journalists pointed out in a BIONET-supported workshop held in 
Changsha in April 2008, this is often more the case in China’s largest cities: 
 
Despite the rising urgency of and media interest in bioethical issues, the media have been 
poorly equipped to report these issues, especially in cities outside Beijing and Shanghai. 
Journalists should not be blamed for the insufficiency, as bioethics issues are related to both 
complicated life science research and difficult ethical issues, such as in the case of how to 
judge whether certain research could cause harms. (SciDevNet 2008: 4) 
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What is clear is that each country – whether in Europe or China – is taking active 
measures to define its ethical and scientific agenda, and indeed to stake their claims to 
sovereignty. Questions about what forms of scientific practice are to be prohibited – e.g. 
therapeutic cloning, export of biological samples or provision of experimental stem cell 
therapies – remain very much anchored in nation states and are often surrounded by 
commercial as well as national interests as nation states vie for competitive advantage. 
Biotechnology and advanced biomedical research have been identified as key strategic 
areas in both the European Union and China (see Gottweis 2009; Ong & Chen 2011). 
 
While there are no formulas for ensuring the ‘best’ or ‘most inclusive’ forms of 
deliberation, there are plenty of lessons learned and best practices to be consulted and 
shared. It is one thing to organise global meetings around questions of bioethics, and 
another to ensure exchange of experiences and ideas between, for example, various 
national ethics councils or committees about how to organise national deliberation. 
Should it be through town hall meetings, expert seminars, media campaigns, etc.? 
Moreover, when scientists enter a cross-cultural collaboration, they are not only bringing 
with them certain sets of expertise, they are also coming from certain traditions and styles 
of debating science direction, something that collaborating partners need to be aware of. 
For example, the question of whether or not research on human embryos should be 
allowed has not been approached in the same way in China as it has been in Germany, yet 
in both countries positions have emerged around this exact question. Dialogue and 
exchange about how various positions have been formed would facilitate the kind of 
cross-cultural dialogue that is a precondition for research collaboration. 
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A boom in bioethical legislation 
In both China and Europe, respective organised processes of ethical deliberation feed into 
national regulatory processes and resulting ethical regulation. Yet, guidelines and 
regulations are never sufficient in themselves for a number of reasons, beyond the 
obvious fact that they require execution to be meaningful and practical. First of all, most 
regulations in advanced biological and biomedical research supplement or specify basic 
civil and criminal law, and fall under the category of ‘soft law’, i.e. they are not directly 
legally enforceable. In Europe, there are often many different instruments used to ensure 
ethical supervision of research. There are international declarations, national laws and 
regulations, the regulations of professional associations, recommendations from national 
ethics councils or commissions, statements of ethical review committees in research 
institutions or hospitals, ethical requirements of public or private funding bodies as well 
as ethical requirements of scientific journals (see De Vries et al. 2007). 
 
[TABLE 1 here] 
 
In China, there has also been somewhat of a ‘legislative boom’ over the past few decades, 
corresponding to the policy of opening and transforming China. A key function of 
legislation at this level is employing standardisation measures as an instrument to foster 
China’s international role as a global player and a modern state, also in life sciences 
research. Almost every bioethical aspect regarding biomedical manipulations (see Table 
1), including those involving human embryonic stem cells, has been covered through 
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guidelines and regulations in order to protect the rights of human subjects and public 
morality, however, most regulations do not enforce legal liabilities (civil or criminal) and 
damages. 
 
As such, we find broad agreement about the fundamental moral concerns and principles 
laid out in both European and Chinese documents – e.g. the protection of subjects from 
abuse, informed consent or mandatory ethical review of biomedical research projects. 
Still, there is a long way from regulation to implementation, a pathway that can be filled 
with obstacles in the form of a lack of capacity or ambiguous or vague formulations and 
that can be manipulated against the regulations’ intentions. As a result, there are often a 
diversity of practices with some best practice institutions having developed strong 
systems for ensuring ethical governance and others still working to build capacity and 
capability. 
 
Another weak aspect of regulation relates to the process of formulating them. When 
compared to the fast pace of scientific discovery and research, regulation is usually 
lagging behind. It can be a laborious and slow process to prepare legislation related to life 
sciences research involving human subjects not least since it often overlaps the areas of 
different Ministries/Directorate Generals and also since formulating laws and regulations 
involved consultations with numerous experts from the legal, bioethical, social and 
medical fields (see Sariola & Simpson 2011). 
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On the other hand, harmonisation processes, partly spurred on by international 
collaborations can often be used to ‘raise the bar’. For instance, if a multi-centre clinical 
trial involves partners from countries in Europe and China, principal investigators may 
require that the most stringent ethical requirements are followed, leading partners in other 
countries to strengthen their ethical governance practices while still complying with 
national requirements. However, one must not overlook the close ties that private biotech 
and pharmaceutical companies can have with regulators and indeed the ways in which 
industry lobbies feed into regulatory processes must be accounted for in terms of raising 
or lowering ethical ‘bars’ (see Petryna 2009; Abraham and Reed 2003). 
 
Finally, in the context of global science, a number of regulatory gaps appear as different 
nations adopt different approaches to regulating areas of life science research. That is to 
say, national regulations cannot in themselves prevent or restrict any kind of research in a 
global context of regulatory diversity. For example, some countries are considered to 
have permissive regulation and others restrictive regulation when it comes to stem cell 
research and/or provision of experimental stem cell therapies. Such regulatory diversity 
may create uncertainty and has arguably fuelled both ‘brain drain/gain’ as stem cell 
scientists travel to work in so-called ‘permissive’ countries and ‘stem cell tourism’ as 
patients travel to various parts of the world to receive experimental treatments not 
available in their own countries. The point being that global mobility makes it impossible 
for single nations to prohibit any particular kind of research on their own. Such 
challenges are intensified when multiple regulatory traditions and regimes are brought 
into contact through cross-cultural research collaboration. Cross-continental collaboration 
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inevitably involves multiple legal systems and traditions which in turn calls for clarity 
about which laws and regulations apply to the practices of researchers, something that 
should be clarified from the outset of any research collaboration. 
 
Ethical review 
If the spheres of ethical deliberation and ethical regulation contribute to setting a 
particular legislative and cultural context and/or direction for advanced biomedical 
research in a country, then the building up of ethical oversight mechanisms has become 
an important part of the everyday, nitty-gritty of biomedical research. This is because one 
of the most important instrumental aspects of ethical governance systems is oversight and 
adherence. For it is the principle objective of all ethical governance systems to protect the 
rights, safety and wellbeing of human subjects who participate in biological or 
biomedical research and this implies some kind of oversight of the research process – 
from recruitment of research subjects, carrying out of research, publication of research to 
follow up of research participants. Institutional Review Boards (IRBs) or Ethics Review 
Committees (ERCs) are the two most dominant organisational forms of ethical oversight 
and it is these institutions that scientists will be in direct contact with. 
 
With countries in both Europe and China currently being in the midst of building up such 
systems of ethical oversight, there are plenty of lessons learned to be shared. It is only in 
relatively recent years that ethical review systems have come to be organised at a national 
or trans-national level. In Europe, ethical review boards were established locally on an ad 
hoc basis from around the 1960s, often as a result of public debates about cases of 
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misconduct, scandals or disputed practice (see Hall 1991; Hedgecoe 2009). It was not 
until the 1990s that European governments began taking steps to recognise, consolidate 
and coordinate their work regionally and nationally. The ways in which the work of 
ethics review committees is organised varies greatly from country to country, with some 
emphasising institutional levels and others centralising the task of ethically reviewing 
scientific research.  
 
In China, there has also been an initial focus on establishing institutional review boards 
but the government has stipulated that administrative departments of health at the 
provincial level all set up consultation organizations on ethical review to guide and 
supervise the ethical review by IRBs under their jurisdiction. According to the 
Regulations on Ethical Review of Biomedical Research Involving Human Subjects: 
 
Institutions implementing biomedical research involving human subjects and application of 
relevant technologies, including institutions for medical and health, research, prevention and 
control of diseases, and healthcare of women and children, shall set up IRBs. IRBs shall 
mainly undertake the ethical review and carry out the ethical review and supervision over 
biomedical research involving human subjects and application of relevant technologies by the 
institutions themselves and those subordinate to them and may accept the entrusted review 
according to the demands of society; they may also organize and carry out relevant ethical 
trainings. (MOH 2007: Article 6) 
 
Yet, while a requirement to ethically oversee biological and biomedical research 
involving human subjects has by now been enshrined in national law throughout Europe 
and China, putting such oversight into practice is a process with numerous hurdles and 
challenges – which are again complicated when both regions are interactively connected 
through research collaboration. In China there is great variability of institutional practices 
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under the same standards – just as in the European region. There are good ethical review 
practices in ‘top’ hospitals and laboratories but more problems in less-resourced hospitals 
and laboratories or in differently developed regions. Among the problems identified by 
BIONET in China were: 
 
• Lack of independence – many ethical review committees were chaired by the 
heads of hospitals and external members often did not have voting rights 
• Conflicts of interest arising from researchers’ financial interests  
• Lack of resources to monitor and follow up once research has been approved   
• Researchers tend to give yes/no answers with insufficient commentary on issues 
of researcher qualifications, risk-benefit analyses, informed consent and 
compensation 
• Lack of qualified members for ethical review committees, members may have 
basic training in Good Clinical Practice but not in ethics  
• Lack of resources for ethics committees to train researchers 
• There are still large discrepancies in the quality of informed consent forms, 
examples range from half-a-page to 4-5 pages – insufficient explanation of 
randomisation, placebo, other available treatments, risks, adverse effects 
• No attention to insurance questions – the most frequent source of dispute comes 
from disagreement about compensation if adverse or harmful effects result from 
participating in a clinical trial (BIONET 2010a) 
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In view of these challenges, two constructive proposals have emerged in China: firstly, 
so-called ‘centres of excellence’ could play an important role in promoting and sharing 
their best practices with other less-resourced laboratories and hospitals. Secondly, smaller 
hospitals and laboratories could pool their resources and, for example, form joint ethical 
review committees. 
 
Since cross-continental research collaborations will often involve multiple institutions 
there will be multiple review boards/committees involved as well. And since each 
institution will have its own particular procedures and traditions of operation, 
collaborating scientists will need to ensure that their collaborations are compliant with the 
ethical review requirements of their institutions. This may well require that particular 
review boards/committees specifically address how cross-continental research 
collaborations should be reviewed and also calls for cross-continental exchange of best 
practices and ideas between members of review boards in Europe and China. 
 
Ethical interaction 
A fourth and final sphere or layer of ethical governance consists of the ethical interaction 
which takes place between researchers and research subjects. Ethical interaction consists 
of all those occasions when researchers come into contact and work with voluntary 
research subjects from recruitment to participation and follow up in a particular research 
project. Traditionally, informed consent procedures and forms have been seen as the most 
important tool for ensuring that interaction between researchers and patients is ethical and 
legal. Signed consent forms are used to keep ethical audit trails which, should research 
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subjects suffer from unintended consequences or disagreements arise, researchers must 
be able to produce to document that they have acted in accord with best ethical practice 
standards by communicating due information. 
 
However, in by far most cases (whether in Europe or China), ethical oversight of 
scientific research ends once a research proposal has been ethically reviewed and 
approved. There is little follow up or quality control of informed consent processes, not 
least because of a lack of resources. Yet it is exactly at this stage that research integrity is 
most under pressure from multiple directions. For instance, universities might be 
pressuring senior researchers who in turn might be putting pressure on junior researchers 
to ‘get some results’, conflicts of interest can arise if researchers have financial interests 
in the research at hand, community research projects can have unintended consequences 
on cohesion if certain members of the community are excluded while others are included 
in research projects, and patients may feel that saying ‘no’ to participation will affect 
their access to medical treatment. Moreover, the pressures of limited resources and time 
mean that informed consent processes can quickly become routinised and bureaucratic, a 
matter of signing a form with minimal interaction around and explanation of intended 
research. 
 
While the limitations of informed consent forms and procedural ethics have been 
discussed at length by many scholars (see Molyneux et al. 2005; Geissler & Molyneux 
2011; Ong 2011), what has been less examined is exactly whose role it should be and 
how to ensure that ethical interaction takes place in an ethically acceptable and 
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transparent manner when cross-cultural research collaborations are initiated (a notable 
exception is Christakis 1992). Since what is particularly at stake in this sphere of ethical 
interaction are forms of communication and relationship between doctors and patients or 
scientists and donors, European researchers who work in China and vice versa will be 
faced with the challenge of understanding the cultural particularities of such interaction 
when designing their informed consent procedures and in general ethically sensitizing 
their research projects. What we found through our mapping exercise in the fields of stem 
cell, clinical and genomic research is that: 
 
1. There is no ready-made answer as to which situations will automatically lead to 
unethical interaction, but a willingness to acknowledge and analyse potential 
pitfalls before, during and after research can help ensure that measures are taken 
to counteract these. A great deal of collaborative social science research and 
conceptual reflection will be necessary in order to work out the multi-faceted 
realities to which ethical governance needs to respond on the ground, especially 
so in cross-cultural collaborations where researchers may be unfamiliar with the 
legal, cultural, socio-economic and linguistic settings they are working in. 
2. When it comes to recruitment of volunteers, particular attention needs to be paid 
to how questions of who has the capacity to consent and the authority to consent 
are negotiated in a given socio-economic and/or cultural context. Since this can 
change from region to region within a country, scientists must ensure that cultural 
differences are taken into consideration when they design their consent 
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procedures, and importantly ensure that all those involved with recruiting 
volunteers and interacting with them respect cultural sensitivities. 
3. Ethical interaction between researchers and research subjects in situations where 
biological samples are procured requires respect as well as social and cultural 
sensitivity, and donor safety will always be the prime concern (see Rehmann-
Sutter 2011). Likewise when biographical, life style or family medical history is 
obtained from donors through interviews or questionnaires, due social and 
cultural sensitivity is a requisite.  
4. A great deal of thought must be put into study designs and communication with 
communities and potential research subjects. For example, what might seem like 
administrative technicalities on paper (e.g. study inclusion criteria) can have 
unintended stigmatizing consequences in a community (see Patra and Sleeboom-
Faulkner 2010). 
 
Conclusions 
In this article, we have argued that an intensification of cross-continental biomedical and 
biological research collaborations has generated an urgent need to address questions 
around the ethical governance of biomedical research collaborations (cf. Geissler et al. 
2008; Sleeboom-Faulkner & Hwang 2012). Whereas the idea behind a ‘global bioethics’ 
is that a minimum of common ground can be identified and formulated across countries 
and cultures, ethical governance of biomedical research collaborations takes its point of 
departure in actual practices in specific fields around the world. If global bioethics has 
been critiqued as an imposition of a ‘Western’ or ‘universal’ ethical framework that is 
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external, detached or alien to a given situation, then this is partly because of the fact that 
individual countries are actively building up national systems of ethical governance. 
When there is collaboration, (rather than being imposed) such systems presumably meet 
and are required to co-operate and communicate. One of the first steps in addressing the 
challenges of collaboration is carrying out the kind of mapping exercise we have as a way 
to improve understanding of what it is that each partner organisation is ‘bringing to’ the 
collaboration. 
 
As a way of organising the complexity of global research collaborations, we have found 
it helpful to delineate four distinct spheres relevant in the context of ethical governance of 
biomedical and biological research – namely those of ethical deliberation, ethical 
regulation, ethical oversight and ethical interaction. When researchers enter into cross-
continental biomedical research collaboration, they are bringing with them their own 
experiences from these spheres as found in their own national settings. And what we 
suggest is that, this must be taken into account in the planning, execution, management 
and oversight of research collaborations. A number of concrete avenues for future 
attention emerge, which we put forth here as our conclusion: 
 
Accountability and clarity – some forms of biomedical research are allowed in some 
countries but not in others – e.g. creation of embryonic stem cell lines or therapeutic 
cloning. As a consequence, what matters most for the governance of research 
collaboration between Europe and China (or between any other countries or regions) and 
also within these regions, is that all research should take place accountably within clear 
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national regulations and ethical frameworks there should not be any ambiguity as to 
which regulations are applicable. 
 
Ethical capacity building of principal investigators – ethical review committee members 
have long been targeted for capacity building. Yet ethical, cultural and social capability 
development is not only something that should be directed at such members, rather 
ethical capacity building should also be provided for principal investigators of research 
projects and other relevant research staff, as it is they who will be identifying and 
analysing their target populations for study recruitment. Moreover, while ethical review 
of research projects before they commence is of course important, perhaps more 
important is to set up mechanisms for ethical oversight through the duration of a 
scientific project (e.g. quality control of informed consent procedures, interviews with 
research subjects and researchers), and evaluation afterwards. 
 
Inter-disciplinary collaboration in biomedical research – social sciences can contribute 
through in depth, empirical research among participants in advanced life science research 
projects to help identify ethical challenges arising from researcher-research subject 
interaction in particular settings. In particular, they can enhance the soft skills required in 
ethical governance and communication between cultures. Ethical review requirements 
could include social scientific inputs into the identification of potential ethical problems 
arising from biomedical research. 
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Table 1 
 
China’s growing bioethical regulatory framework 
 
The Chinese legal system consists of a range of different regulatory instruments. Laws (fǎ 
法) are passed by the People’s Congress or its standing committee and are fully 
enforceable by the responsible institution specified in the law. Regulations (tiáo lì 条例) 
are approved by the State Council and are also enforceable. Technical norms or standards 
(jì shù guī fàn 技术规范) which are intended to ensure safety and effectiveness, and 
ethical principles (lún lǐ yuán zé 伦理原则) which are intended to maintain social order, 
on the other hand are only enforceable if they are specifically authorized in the text of a 
law or regulation. Finally, there are also administrative measures (guǎn lǐ bàn fǎ 
管理辦法) which are directed at the administration and management of certain research 
and therapeutic practices and which are binding for those institutions, which are licensed 
to carry out these practices. 
 
As concerns life sciences research these have been some of the key regulatory 
stipulations concerning biological sample collection, manipulation of human biological 
materials and testing of biological therapies on humans: 
 
1998: Interim Procedures for Human Genetic Resources Administration (State Council, 
Ministry of Science and Technology and Ministry of Health) led to the establishment of 
the Chinese Human Genetic Resources Administration Office. These procedures were 
strengthened in 2003 and they specify rules for exporting and importing genetic 
materials. 
2003: Regulations on Standards and Norms for Clinical Drug Research Quality Control 
(State Food and Drug Administration) established Good Clinical Practice guidelines 
including protection of research participants 
2003: Ethical Guiding Principles for Research on Human Embryonic Stem Cells 
(Ministry of Science and Technology and the Ministry of Health) set out guidelines for 
what kinds of research and manipulation would be acceptable 
2004: Administrative Measures on Biosafety in Laboratories with Pathogenic 
Microorganisms (State Council, Ministry of Science and Technology) 
2007: Regulations on Misconduct in Scientific Research (Ministry of Science and 
Technology), led to the establishment of a science ethics committee and a supervision 
office to stem academic fraud and plagiarism. 
2007: Regulations on Ethical Review of Biomedical Research Involving Human Subjects 
(Ministry of Health) 
2009: Administrative Measures on Clinical Applications of Medical Technologies 
(Ministry of Health), prohibits clinical use of embryonic stem cells and introduces new 
approval procedures for autologous stem cell therapies. 
2010: Guidelines on Ethical Review of Drug Clinical Trials (Ministry of Health and State 
Food and Drug Administration) 
